MUC1 Peptide-Poly-ICLC Vaccine
Phase 2Vaccine
MUC1 Peptide-Poly-ICLC Vaccine is one of 18 biologic programs targeting Colorectal Adenoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Lung Carcinoma
#DrugCompanyPhaseTrials
1Lumakras
AmgenApproved
Iressa
AstraZenecaApproved
Afinitor
NovartisApproved
Chantix
PPrism Pharmaceuticals
Approved
Aurlumyn
BBTG International Inc.
Approved
Navelbine
PPierre Fabre Medicament
Approved
Leukine
SanofiPhase 2
Nicorette
PfizerPreclinical
MUC1 Peptide-Poly-ICLC Vaccine
NNational Cancer Institute (NCI)
Phase 2
Montanide ISA 51 VG
NNational Cancer Institute (NCI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)